Machida H, et al. - In this retrospective study, the survival outcomes of women with recurrent cervical cancer who received salvage chemotherapy with modified dose-dense paclitaxel (MDDP) monotherapy (paclitaxel 80 mg/m², administered on day 1, 8, and 15 without day 22) were analyzed. For this investigation, they assessed cause-specific survival after the first recurrence in women with recurrent cervical cancer diagnosed between 2006 and 2014. For recurrent cervical cancer, MDDP monotherapy is a tolerable and relatively effective regimen.